 FOSTER CITY, Calif. MECHELEN, Belgium--BUSINESS WIRE--Gilead Sciences, Inc. Nasdaq: GILD and Galapagos NV Euronext Nasdaq: GLPG today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca filgotinib. This announcement follows a Type A meeting with the U.S. Food and Drug Administration FDA to discuss the points raised in the Complete Response Letter CRL related to the New Drug Application NDA for f 